Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Myovant

Myovant, Accord Healthcare Ink Relugolix Distribution Pact For Europe In Prostate Cancer

Myovant Sciences Ltd (NYSE:MYOV) and Accord Healthcare Ltd have entered into an exclusive license agreement to commercialize Orgovyx (relugolix) for advanced hormone-sensitive prostate cancer in the European Economic Area, the U.K., Switzerland, and Turkey. Accord has the right to the first negotiation if Myovant decides to enter into licensing arrangements in countries in the Middle…

Benzinga · May 9, 2022

U.S. FDA extends review of Pfizer and Myovant Sciences supplemental New Drug Application (sNDA) For MYFEMBREE by three months

The U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) from Pfizer Inc.

Benzinga · May 6, 2022

Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer

Myovant Sciences Ltd (NYSE:MYOV) received European approval for Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer, and SVB Securities think Orgovyx could be a ~$1 billion product in advanced prostate cancer long term. But the surprise Myfembree setback in endometriosis has sparked uncertainty and new investor questions for Myovant's 2nd program. Hence, SVB remains on the…

Benzinga · May 2, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

What's Going On With Myovant Sciences Stock Today?

Myovant Sciences Ltd (NYSE: MYOV) shares are trading significantly lower Tuesday after the company and Pfizer Inc (NYSE: PFE) announced an update on the Supplemental New Drug Application for MYFEMBREE for the manag

Benzinga · Apr 12, 2022

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.